Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -9.48% and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Flat results in Sep 26
Risky - Negative EBITDA
Stock DNA
Pharmaceuticals & Biotechnology
INR 123 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
-1.33
7.82%
-0.72
Total Returns (Price + Dividend) 
Krebs Biochem for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Krebs Biochemicals & Industries Ltd Downgraded to Sell Amid Mixed Technicals and Weak Fundamentals
Krebs Biochemicals & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Nov 2026, driven primarily by improvements in technical indicators despite persistent fundamental weaknesses. The company’s micro-cap status and challenging financial trends continue to weigh on its outlook, but recent technical signals have prompted a more favourable stance from analysts.
Read More
Krebs Biochemicals & Industries Ltd Forms Golden Cross Amid Mixed Technical Signals
The 50-day moving average has crossed above the 200-day moving average for Krebs Biochemicals & Industries Ltd, signalling a golden cross on 16 Nov 2026. Yet, the stock’s modest 0.20% gain on the day and a patchwork of technical indicators suggest the signal is far from straightforward — is this a genuine shift in momentum or a lone signal amid mixed evidence?
Read More
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
Krebs Biochemicals & Industries Ltd is rated 'Strong Sell' by MarketsMOJO, a rating that was last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 October 2026, providing investors with an up-to-date perspective on its performance and outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
30-Oct-2026 | Source : BSEThe Company has enclosed herewith copy of newspaper advertiement for financial results for the quarter ended 30.09.2026
Result For The Quarter Ended 30.09.2026
29-Oct-2026 | Source : BSEFinancial Results for the quarter ended 30.09.2026
Board Meeting Outcome for Outcome Of Board Meeting Held On 29.10.2026
29-Oct-2026 | Source : BSEOutcome of the Board Meeting for consideration of unaudited financial results for the quarter ended 30.09.2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Krebs Biochemicals & Industries Ltd has announced 21:100 rights issue, ex-date: 31 Jan 19
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 1 FIIs (0.49%)
Ipca Laboratories Limited (49.65%)
Sun Pharmaceutical Industries Ltd (4.81%)
19.63%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 38.85% vs -67.57% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 12.05% vs -6.60% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -62.51% vs 1.06% in Sep 2024
Growth in half year ended Sep 2025 is -4.94% vs -22.81% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is -54.53% vs -3.22% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 21.80% vs -34.51% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is -45.21% vs -14.10% in Mar 2025
YoY Growth in year ended Mar 2026 is 37.16% vs -36.54% in Mar 2025